1 e, we extend these preclinical findings by a
first-in-human (
11)C-metformin PET dosimetry, biodistrib
2 First-in-human (
68)Ga-PSMA I&T PET imaging allowed high-
3 We assessed pre-clinical toxicology and
first-in-human administration of C34-PEG4-Chol.
4 First, in humans and animals, activation of the immune s
5 nclude children younger than age 18 years in
first-in-human and other adult cancer clinical trials.
6 of CCR5 using zinc finger nucleases was the
first-in-human application of genome editing and remains
7 ition of [(11)C]-(R)-3 in primates including
first-in-human assessment.
8 The probability of a
first-in-human at 10 years was 9.8%.
9 In this
first-in-human case study, the combination successfully
10 First-in-Humans case series.
11 Here, we report the
first-in-human characterization of 2 new PDE10A radiolig
12 l products are currently being developed for
first in human clinical trials in select disorders.
13 To the best of our knowledge, this is the
first in-human clinical trial to assess the safety, tole
14 We report the
first-in-human clinical experience with a novel preforme
15 isease (CUPID 1) study was a phase 1/phase 2
first-in-human clinical gene therapy trial using an aden
16 First-in-human clinical studies of recombinant human IL-
17 ate preclinical evidence prior to initiating
first-in-human clinical studies.
18 In a
first-in-human clinical study ILIT with MAT-Fel d 1 was
19 ally re-induce HbF by DNMT1 inhibition, this
first-in-human clinical trial (NCT01685515) combined 2 s
20 In conjunction with the phase 1
first-in-human clinical trial of venetoclax in patients
21 Purpose We performed a
first-in-human clinical trial on ultrasound molecular im
22 silica particle was recently approved for a
first-in-human clinical trial.
23 (68)Ga-NOTA-2Rs15d is ready for
first-in-human clinical trials.
24 ecies to establish safe starting dosages for
first-in-human clinical trials.
25 In this
first-in-humans clinical trial of a purified recombinant
26 We conducted the
first-in-humans clinical trial of chimeric antigen recep
27 , and thus for marrow homing, we conducted a
first-in-humans clinical trial to correct this deficienc
28 In a "
first-in-human"
clinical trial, we evaluated the safety
29 These
first-in-human data introduce a novel macrophage-specifi
30 e conjugate currently tested in a phase 1/2a
first-in-human dosage escalation trial for patients with
31 In this phase 1,
first-in-human dose-escalation and dose-expansion study,
32 This
first-in-human dose-escalation study assessed the maximu
33 This
first-in-human dose-escalation trial in 25 previously tr
34 onuclide conjugate currently in a phase 1/2a
first-in-humans dose escalation trial for patients with
35 This
first-in-human,
dose-escalation and expansion study eval
36 In this
first-in-human,
double-blind, randomized placebo-control
37 This is the
first-in-human evaluation of a novel aptamer antagonist
38 Development Program (IPCAVD) 001 trial, the
first-in-human evaluation of a prototype Ad26 vector-bas
39 adiation dosimetry for (68)Ga-NOTA-UBI and a
first-in-human evaluation to diagnose infectious process
40 The radiotracer is currently undergoing
first-in-human evaluation.
41 Here, we summarize the
first-in-human experience in 3 heavily pretreated patien
42 These observations represent a
first-in-human experience of an RNA aptamer and its comp
43 This study presents, to our knowledge, the
first-in-human experience with (18)F-FEOBV, including ra
44 ical potential of (64)Cu-DOTATATE in a small
first-in-human feasibility study.
45 tion-approved trial, "A Phase 1, Open-Label,
First-in-Human,
Feasibility and Safety Study of Human Sp
46 covery of biomarkers of drug activity before
first in human (
FIH) studies.
47 f the design, implementation, and outcome of
first-in-human (
FIH) trials of monoclonal antibodies (mA
48 In addition, the
first-in-humans (
FIH) dose of 485 mg, determined from th
49 The authors describe a
first-in-human,
fully percutaneous superior cavopulmonar
50 First, in human heart transplant recipients the total le
51 This
first-in-human HF efficacy/safety study demonstrates an
52 We therefore undertook a
first-in-human HF proof of concept/safety study, evaluat
53 shed both in vitro and in vivo, warranting a
first-in-human investigation in psoriasis.
54 the myocardium of this radiotracer, and the
first-in-human measurements of MBF performed in 7 health
55 This phase I,
first-in-human,
non-randomized, open-label study evaluat
56 CALM-FIM_EUR was a prospective,
first-in-human,
open-label study done at six European ce
57 First, in human peripheral blood T cells (PBT), expressi
58 ic profile, PF-06282999 has been advanced to
first-in-human pharmacokinetic and safety studies.
59 Here we report results of a
first in human phase 1 trial of XmAb5574 in patients wit
60 We are at present conducting the
first in-human phase I clinical trial involving the syst
61 A
first-in-human phase 1 clinical study was performed on 1
62 This
first-in-human phase 1/2 study assessed the maximum tole
63 Data were combined from part 2 of a
first-in-human phase 1/2 study of patients who relapsed
64 apy and in combination with gemcitabine in a
first-in-human phase I clinical trial in patients with a
65 This
first-in-human phase I study assessed safety, tolerabili
66 the rate-limiting steps is the initiation of
first-in-human (
phase I) trials.
67 SCIPIO is a
first-in-human,
phase 1, randomized, open-label trial of
68 Conclusion: This
first-in-human,
phase I clinical trial demonstrates the
69 This
first-in-human,
phase I clinical trial demonstrates the
70 The aim of this
first-in-human,
phase I clinical trial was to investigat
71 This
first-in-human pilot study shows that molecular imaging
72 We aimed to report results of the
first-in-human proof-of-concept clinical trial in health
73 This
first-in-human proof-of-concept study evaluated the clin
74 ese advances have recently culminated in the
first-in-human PSC clinical trials by Geron, Advanced Ce
75 Finally, we present
first-in-human results demonstrating non-invasive imagin
76 The favorable tracer biodistribution and the
first-in-human results will make (68)Ga-NOTA-UBI PET/CT
77 ntraoperative detection and resection during
first-in-human RGS.
78 We report the
first-in-human safety and immunogenicity assessment of a
79 We report the
first-in-human safety and immunogenicity assessment of a
80 We report the
first-in-human safety and immunogenicity evaluation of P
81 This
first-in-human series demonstrated that temperature-cont
82 In this
First-in-Human series, diaphragm pacing with a temporary
83 These data are the
first in humans showing that hormone-regulated vitamin s
84 In this multicentre phase 1b,
first-in-human,
single-blind, placebo-controlled trial,
85 e gliomas (HGG) are frequently excluded from
first-in-human solid tumor trials because of perceived p
86 nsive, and early study of novel drugs at the
first-in-human stage and the study of established drugs
87 In this
first-in-human strategy, 10 patients with stage IV melan
88 hildren have historically been excluded from
first-in-human studies of promising new cancer drugs and
89 rs, New York, NY) to identify any associated
first-in-human studies published by January 2015.
90 First-in-human studies with clinical-grade (18)F-FTC-146
91 First-in-human studies with PSMA radioligands derived fr
92 For these
first-in-human studies, an activating peptide for the hu
93 eier curves were constructed for the time to
first-in-human studies.
94 A
first in human study to evaluate tolerability and pharma
95 In this
first in-human study of a systemically administered near
96 Nevertheless, the safety profile of this
first in-human study of the humanized mAb to IL-2/IL-15R
97 involvement was a significant predictor of a
first-in-human study (P = 0.02); devices developed with
98 This
first-in-human study aimed to assess the safety, tolerab
99 Here we present the results of a
first-in-human study assessing the safety and effectiven
100 This
first-in-human study demonstrated safety, dosimetry, bio
101 This
first-in-human study evaluated the safety, pharmacokinet
102 This multicenter,
first-in-human study evaluated the safety, tolerability,
103 This phase I,
first-in-human study evaluated the safety, tolerability,
104 This
first-in-human study evaluated the safety, tolerability,
105 This
first-in-human study evaluates the safety, pharmacokinet
106 This
first-in-human study in previously treated subjects with
107 ve of FLT3-ITD mutation status in a phase I,
first-in-human study in relapsed or refractory AML.
108 This
first-in-human study investigated the safety, tolerabili
109 We conducted the
first-in-human study of (18)F-fluoroethyl triazole [Tyr(
110 We conducted a
first-in-human study of (18)F-MFBG PET imaging to evalua
111 This
first-in-human study of RTH258 demonstrated noninferiori
112 This
first-in-human study of T-DM1 evaluated safety, pharmaco
113 This was a
first-in-human study of the novel phosphodiesterase-2A (
114 It was a
first-in-human study of the poly (ADP-ribose) polymerase
115 In a previous
first-in-human study of venetoclax, 77% of patients with
116 present work, FR104 has been evaluated in a
first-in-human study to evaluate the safety, pharmacokin
117 A phase I
first-in-human study was conducted to characterize the s
118 A
first-in-human study was conducted to evaluate the feasi
119 This
first-in-human study was designed to evaluate the safety
120 Purpose This two-part,
first-in-human study was initiated in patients with adva
121 Objectives of this
first-in-human study were to characterize the safety, ph
122 In this
first-in-human study, Chapuis et al. demonstrate that th
123 In what we believe to be a
first-in-human study, we evaluated the safety and dosime
124 in serum of ulcerative colitis patients in a
First-In-Human study.
125 terize the pharmacodynamic responses in this
first-in-human study.
126 These data led to a 2-part
first-in-human study: Part I evaluated safety and pharma
127 This
first-in-humans study supports the clinical use of (64)C
128 We report the
first-in-human successful transcatheter tricuspid valve
129 herefore, this radiotracer is suitable for a
first-in-human theranostic application and may help to i
130 First-in-human,
to our knowledge, [(18)F]CFA PET/CT stud
131 Recently, we started the
first-in-human treatment with an alpha-radionuclide-labe
132 in-17 (anti-IL-17) monoclonal antibody, in a
first in-human trial in rheumatoid arthritis (RA) patien
133 ffects of NK cells post-HSCT, we conducted a
first-in-human trial of adoptive transfer of donor-deriv
134 Thus, in preparation for a
first-in-human trial of mesenchymal stromal cells (MSCs)
135 The main aims of this
first-in-human trial were to determine maximum-tolerated
136 In a recent,
first-in-human trial, the study was activated and the fi
137 In a
first-in-human trial, we recruited five patients at the
138 anitumab was similar to that observed in the
first-in-human trial.
139 ntibody (ozanezumab) was well tolerated in a
first-in-human trial.
140 Compound 7 was advanced to
first-in-human trials for the treatment of diabetic neph
141 ities and practical steps that would lead to
first-in-human trials of lung cell therapy.
142 this issue of Blood, Uchida et al report the
first-in-human use of a new nonsubstitutive therapy for
143 This paper provides results from
first-in-humans use of (64)Cu-DOTATATE, an avidly bindin